"Two Indian pharma companies will partner to manufacture medicines on HIV/AIDS produced by foreign companies following which the the cost would reduce by 75 to 99 per cent compared to the international market. They will be launched during the 3rd National Conference of AIDS Society of India (ASICON 2010) to be held in Hyderabad from October 29," the society's secretary I S Gilada said.
"There is no medicine which can cure this disease. But now India will have the treatment which can get patient to come out from worst to a better stage," he said.
"Emcure will also come up with new medicines that can be used for children suffering from HIV/AIDS during the conference," he said.
Another formulation 'Isentress' (raltegravir), an antiviral medication that prevents human immunodeficiency virus (HIV) cells from multiplying in the body, would be manufactured and marketed in India by Merck at a low price, he said.
"India has shown a ray of hope to millions of HIV positive people worldwide by virtue of its cheaper antiretroviral treatment (ART) without compromising on quality," Gilada said.
The yearly per patient ART cost of $10,452 a decade earlier, has has been brought down to a mere $69 for the first-line combination ART, that is merely 0.7 per cent of international cost, he said.